The U.S. Food and Drug Administration (FDA) has announced an "ultra-fast" review of three psychedelic drugs aimed at treating mental health conditions, including depression and post-traumatic stress disorder (PTSD). This accelerated process follows an executive order signed by President Donald Trump last weekend, which seeks to expand access and reduce restrictions on psychedelics currently classified as illegal under federal law.
The FDA awarded priority review vouchers for psilocybin, the active compound in magic mushrooms, for difficult-to-treat depression, and for methylone, a substance related to MDMA, for PTSD. These actions reflect growing bipartisan support for mind-altering substances, particularly among Trump's supporters, including combat veterans and the "Make America Healthy Again" movement championed by Health Secretary Robert F. Kennedy Jr.
In addition, the FDA has authorized initial testing of a drug related to ibogaine for alcohol use disorder. Reports indicate that podcaster Joe Rogan played a role in influencing President Trump's interest in ibogaine, which is derived from an African shrub and has shown promise in treating addiction.
The executive order and subsequent FDA decisions mark a significant shift in U.S. drug policy, potentially opening the door to new treatments for millions of Americans suffering from mental health and addiction disorders. Critics, however, caution that the rapid review process may bypass important safety protocols, while supporters argue that existing treatments have failed many patients and that these substances offer new hope.
